We recently learnt the disappointing news that the company developing Raxone (a potential treatment for delaying the loss of respiratory function in patients with Duchenne muscular dystrophy) was ending its development programme for this drug.
The company will soon be providing charities with more information about what this means for people who have been involved in the clinical trial, SIDEROS, and for people accessing Raxone through the Early Access to Medicines Scheme. We will share more information as soon as we can.
We are here for you. Please contact our helpline on 0800 652 6352 or at email@example.com if you have any queries or concerns about this news.